Results:
The pathological diagnoses were as follows: 45 (85%) adenocarcinomas, 5 (10%) squamous cell carcinoma, 1 (2%) adenosquamous carcinoma, 1 (2%) atypical carcinoid, and 1 (2%) small cell carcinoma. There were 15 (28%) invasive lung cancer cases. Multivariate analysis showed tumor size (P=0.02) and max SUV (P=0.003) to be independent predictive factors of invasive lung cancer. The proportion of patients with a max SUV value greater than 3.0 was significantly higher in invasive lung cancer cases. When the threshold value of max SUV was set at 3.0, the sensitivity for predicting an invasive lung cancer in solid lung nodules was 93% (14/15), with a specificity of 42% (16/38). The positive predictive value was 39% (14/36) and the negative predictive value was 94% (16/17). In the follow-up, 3 of 53 (6%) patients experienced a recurrence of the cancer within two years, and the preoperative max SUV value of all of these patients was greater than 8.0.
Conclusions:
We found that PET-CT results were correlated with pathological severity in small solid lung cancers. In the preoperative assessment, solid lung cancers with high max SUV values were recommended for a standard resection.
Results: During and after procedures we observed in 28% patients hypoxemia, in 23 % hemorrhage 250 cm 3 and more, in 10% arytmias, in 5% patients we observed hypertension and in 2% patients developed after procedure respiratory failure and both patients were 24 hours on invasive ventilation. Two patients died due complications after procedure. Any complications we observed in 40% of all procedures. The procedure leads to improvement of symptoms in 80% patients. The difference in number of complications in patients with ASA III and with ASA IV was not statistically significant (p=0.009). Conclusions: Endobronchial treatment (electrosurgary and laser brochoscopy) leads to improvement of symptoms in 80% patients. This treatment procedure in general anesthesia with jet ventilation is therapeutic procedure with acceptable rate of complications in patients with endobronchial growth of malignancies and in patients with ASA classification III and IV.
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Pathology and Bronchoscopy, Mon, 16:00 -17:30
Flexible bronchoscopy in lung cancer
Leite, Andre G. Bronchoscopy is usually performed under topical anesthesia with or without sedation to promote patient comfort and the ideal conditions for the physician to perform the examination. The objective of the study was to establish which anesthetic procedure used during flexible bronchoscopy for lung cancer diagnostic has the lowest index of complications. Methods: This prospective randomized study analyzed 80 patients that underwent flexible bronchoscopy for lung cancer diagnostic. Patients were randomly assigned to four groups of 20 patients each according to the anesthetic combination used: 200 mg topical lidocaine (LID group); 200 mg topical lidocaine and 2 mg/kg propofol (PPF group); 200 mg topical lidocaine and 20 mcg/kg alfentanil (ALF group); or 200 mg topical lidocaine and 0.05 mg/kg midazolam (MID group). Scores were assigned to patients according to the different variables observed during the bronchoscopic procedure; the lower the score, the lower the complication index. Results: Results of the composite score (mean and standard deviation) for the evaluation of the variables observed during flexible bronchoscopy were 4.6"b3.9 for the PPF group, 7.9"b6.6 for the ALF group, 10.0"b4.5 for the LID group, and 11.3"b5.8 for the MID group (p=0.001). Conclusions: Results showed that the combination of propofol and topical lidocaine was a superior anesthetic method for flexible bronchoscopy than lidocaine alone or in association with midazolam or alfentanil. Clinical Implications: The choice of an effective and low morbidity anesthetic method is basic for the success of a diagnostic flexible bronchoscopy. This study it demonstrated the superiority of the association of propofol and topic lidocaine in the anesthesia for flexible bronchoscopy in lung cancer patients.
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Estrogen receptor overexpression in non-small cell lung cancer is associated with better survival in males. Background: Adenocarcinoma of the lung is more frequent in females than in males and the association with smoking is less pronounced than for the other histological subtypes of lung cancer. Thus other factors than smoking may be involved in the carcinogenesis of lung cancer. Estrogen induction of cellproliferation has been found in for example breast adenocarcinoma and since estrogen receptors (ER) have been demonstrated in lung tumours, a similar role of estrogens in the development of lung cancer has been suggested. Whereas ERalfa plays a key role in adenocarcinomas of the breast, several studies indicate a more predominant role of ERbeta in lung cancer. We examined the expression of ERalfa, ERbeta, and Progesterone in a well defined Danish cohort of patients with NSCLC with more than 15 years of follow up, and related the results to gender and survival. Methods: Paraffin embedded, histological material was collected from 104 patients (71 men and 33 women), operated in the period 1989-1992 for NSCLC (56 squamous cell carcinomas, 40 adenocarcinomas and 8 large cell carcinomas). Sixtythree patients were in stage I, 14 patients in stage II, 24 patients in stage IIIA, and 3 patients in stage IIIB. ERalfa (clone 1D5, DAKO), ERbeta (clone PPG5/10, DAKO) and Progesterone (clone PgR 636, DAKO) were immunohistochemically analyzed. Staining frequency and intensity was scored semiquantitatively. A tumour was defined as positive when more than 10% of the tumour cells were positive with at least a weak nuclear staining. Kaplan-Meier survival curves were generated to evaluate the significance of ERalfa, ERbeta and Progesterone expression for the prognosis. Results: ERbeta positivity was demonstrated in 69% (72 of 104) of the tumours. There was no statistically significant correlation between ERbeta positivity and age, sex, stage, or histology. After adjusting for sex, age, stage at diagnosis and histology there was no difference in survival between subjects with ERbeta-positive and ERbeta-negative tumours. Analysis was repeated after stratifying by sex. Women with ERbetanegative tumours had a non-significant (p=0.26) decrease in mortality compared with women with ERbeta positive tumours. In contrast, men with ERbeta positive tumours had a reduced mortality (p=0.03) compared to men with ERbeta negative tumours (see Figure) .
